Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis
ConditionRheumatoid Arthritis (RA)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorLuo Yaping
About this trial
This study proposes to evaluate 99mTc-CTR-FAPI SPECT imaging as a cost-effective, low-radiation, and widely accessible alternative to 68Ga-FAPI PET/CT for assessing synovial lesions in RA patients, aiming to validate its diagnostic consistency with both PET/CT and physical examinations while correlating imaging findings with clinical disease activity metrics to establish a practical tool for long-term RA monitoring.
Eligibility criteria
Qualifiers
Age: 18-75 years old;
Meet the classification criteria for rheumatoid arthritis of the American College of Rheumatology/European Union for Rheumatology in 2010;
The highest disease activity in clinical practice (CDAI or SDAI score
Disqualifiers
Patients with other autoimmune diseases;
Patients with concurrent tumors;
Women who are pregnant or planning to become pregnant, women in the preconception period, pregnant and lactating women, and women with child-rearing plans during the study period; Subjects of childbearing age need to take effective contraceptive measures during the research process;
Active infection
Trial design
Treatments tested in this trial
- 68Ga-FAPI PET/CT and 99mTc-CTR-FAPI SPECT
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Luo Yaping
Lead sponsor
Peking Union Medical College Hospital
Sponsor institution
Peking Union Medical College Hospital
Collaborator
Source ClinicalTrials.gov